Replies to post #16998 on BioCurex, Inc.(fka BOCX)

[Gold Seeker]

Half: "We have been privied to only portions of the Inverness and Abbott Contracts." We have seen all there was to the Abbott contract since none of it had requested "CT" status and if you noted, no asterisks. The Abbott contract does not matter unless once again, Abbott starts work on the project. As for the Inverness contract, there portions of the document small items deleted that refer to amounts paid. As to a whole section being missing on milestones? Forget it.


http://www.metrocorpcounsel.com/current.php?artType=view&artMonth=January&artYear=2006&EntryNo=4103

<<The SEC will deny as overly broad confidential treatment requests covering lengthy portions of agreements where you do not demonstrate that the omission is appropriate. Omissions will only be acceptable where you provide analysis explaining why the disclosure would be commercially harmful and why disclosure is not necessary for the protection of investors. The narrower you make your request, the more likely it will be accepted.>>

[opportunityknocking]

A little perspective on more of a macro level. Just a few examples, however, I and many others could provide many more:
stock today 52wk high 52wk low sector
uyg 10.61 55.80 7.31 banking index etf
ure 12.22 47.90 10.28 housing index etf
mos 39.01 163.29 30.10 agricultural stock
qld 36.12 122.75 28.27 nasdaq 100 index etf
astm .29 1.23 .15 stem cells
bocx .20 .79 .12 cancer diagnostics

Bottom line is that there is nothing but pain everywhere you look. Nothing has been off limits. With 7 collaborations don't count us out.